Nagaraja “Sri” Srivatsan Appointed CEO of Endpoint Clinical to Lead Next Phase of Innovation

RALEIGH, N.C., March 20, 2025 /PRNewswire/ — Endpoint Clinical (“Endpoint”), a global leader in randomization and trial supply management (“RTSM”) solutions and a portfolio company of Arsenal Capital Partners, today announced the appointment of Nagaraja “Sri” Srivatsan as its Chief Executive Officer, effective immediately.

Srivatsan, who has served as an Advisor to Endpoint since January 2024 and as Interim CEO since January 2025, has already played a pivotal role in strengthening the company’s sales strategy, innovation roadmap, and overall growth trajectory.

“Sri has demonstrated exceptional leadership, strategic vision, and an unwavering commitment to Endpoint Clinical’s mission and stakeholders,” said Ray Hill, Chair of the Board of Directors and Operating Partner of Arsenal Capital Partners. “After a comprehensive evaluation, it became clear that he is the right leader to drive Endpoint’s next phase of expansion and technological advancement. We are confident in his ability to propel the company forward and create lasting impact for patients, clinical sites, sponsors and partners worldwide.”

As CEO, Srivatsan will focus on advancing Endpoint’s technology suite, expanding its market presence, scaling operations and delivering solutions that enhance and accelerate the clinical trial process.

“I am honored to lead Endpoint at this exciting time and deeply grateful for the trust placed in me by the Board and our outstanding team,” said Srivatsan. “Endpoint is at a pivotal moment in its journey, and I look forward to accelerating our mission of transforming clinical trial management with reliable, innovative, high-quality, and efficient RTSM solutions. Together, we will continue to push the boundaries of what’s possible in clinical research, delivering unmatched service and technology to our partners.”

Before serving as interim CEO, Srivatsan was Senior Vice President and Chief Digital Officer of Research & Development Solutions at IQVIA. He previously held executive roles as Chief Growth Officer at EXL and Venture Partner, Emerging Business Accelerator at Cognizant. With over 30 years of experience driving innovation in clinical trials across CROs, biopharma, and patient-focused solutions, Srivatsan is well-equipped to lead Endpoint Clinical toward its vision of becoming a market leader in the eClinical space.

Endpoint Clinical

Endpoint Clinical is a trusted clinical trial technology and service partner that delivers reliable RTSM solutions. Endpoint seamlessly integrates into clinical trial processes by providing anticipatory and adaptive solutions that proactively mitigate risks. With decades of experience in the field, Endpoint deeply understands the challenges manufacturers face in clinical trials. The company’s tech-forward approach, commitment to innovation, and strategic investments enable it to proactively develop fast and effective solutions, allowing manufacturers to focus on seamless clinical trials. Read more about Endpoint’s solutions at https://www.endpointclinical.com/solutions/.

Arsenal Capital Partners

Arsenal Capital Partners is a leading private equity investment firm specializing in building market-leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised over $10 billion in institutional equity investment funds, completed more than 300 platform and add-on acquisitions, and achieved more than 35 realizations. The firm partners with management teams to build strategically important companies with leading market positions, high growth, and high value-add. For more information, visit www.arsenalcapital.com.

Media Contact:
Keelie Truell
ktruell@endpointclinical.com

Ellen Pavlovsky
epavlovsky@arsenalcapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nagaraja-sri-srivatsan-appointed-ceo-of-endpoint-clinical-to-lead-next-phase-of-innovation-302406481.html

SOURCE Endpoint Clinical